Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate

被引:32
|
作者
Goh, B. K. P.
Chow, P. K. H.
Chuah, K. L.
Yap, W. M.
Wong, W. K.
机构
[1] Singapore Gen Hosp, Dept Surg, Singapore 169608, Singapore
[2] Singapore Gen Hosp, Dept Pathol, Singapore 169608, Singapore
来源
EJSO | 2006年 / 32卷 / 09期
关键词
gastrointestinal stromal tumor; GIST; neoadjuvant; imatinib; Gleevec; response;
D O I
10.1016/j.ejso.2006.06.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: The aim of this study is to review the radiologic, PET scan and pathologic response and the outcome of patients with advanced GIST treated with neoadjuvant IM followed by surgical resection. Materials and methods: We report a case and review 36 patients reported in MEDLINE with advanced GIST treated with neoadjuvant IM followed by surgical resection. Results: Thirty-seven patients with a median age of 56 years (range, 32-76 years) at presentation were treated with neoadjuvant IM. Radiologic response accurately predicted pathological response in 31/36 patients, whereas PET scan was accurate in predicting treatment response in only 6/23 patients. Conclusion: This study demonstrates that the pathologic response of GIST to IM is usually incomplete and does not correlate with the complete response seen on PET scan. This finding suggests that surgical resection will continue to play a vital role in the treatment of patients with advanced disease responding to IM treatment. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:961 / 963
页数:3
相关论文
共 50 条
  • [1] Imatinib mesylate neoadjuvant treatment for rectal malignant gastrointestinal stromal tumor
    Hou, Ying-Yong
    Zhou, Yang
    Lu, Shao-Hua
    Qi, Wei-Dong
    Xu, Cheng
    Hou, Jun
    Tan, Yun-Shan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (15) : 1910 - 1913
  • [3] Highlighting the role of FDG PET scan in early response assessment of gastrointestinal stromal tumor treated with imatinib mesylate
    Abhyankar, Suman A.
    Nair, Narendra
    CLINICAL NUCLEAR MEDICINE, 2008, 33 (03) : 213 - 214
  • [4] Neoadjuvant imatinib therapy in rectal gastrointestinal stromal tumors
    Kaneko, Manabu
    Emoto, Shigenobu
    Murono, Koji
    Sonoda, Hirofumi
    Hiyoshi, Masaya
    Sasaki, Kazuhito
    Shuno, Yasutaka
    Nishikawa, Takeshi
    Tanaka, Toshiaki
    Hata, Keisuke
    Kawai, Kazushige
    Nozawa, Hiroaki
    SURGERY TODAY, 2019, 49 (06) : 460 - 466
  • [5] Approval Summary: Imatinib Mesylate in the Treatment of Metastatic and/or Unresectable Malignant Gastrointestinal Stromal Tumors
    Cohen, Martin H.
    Farrell, Ann
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2009, 14 (02) : 174 - 180
  • [6] Imatinib Mesylate: Past Successes and Future Challenges in the Treatment of Gastrointestinal Stromal Tumors
    Ksienski, Doran
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 365 - 379
  • [7] Pathologic complete response confirmed by surgical resection for liver metastases of gastrointestinal stromal tumor after treatment with imatinib mesylate
    Seiji Suzuki
    Koji Sasajima
    Masayuki Miyamoto
    Hidehiro Watanabe
    Tadashi Yokoyama
    Hiroshi Maruyama
    Takeshi Matsutani
    Masaru Hosone
    Shotaro Maeda
    Takashi Tajiri
    World Journal of Gastroenterology, 2008, (23) : 3763 - 3767
  • [8] Approval Summary: Imatinib Mesylate in the Adjuvant Treatment of Malignant Gastrointestinal Stromal Tumors
    Cohen, Martin H.
    Cortazar, Patricia
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2010, 15 (03) : 300 - 307
  • [9] Gastrointestinal stromal tumors: Overview of pathologic features, molecular biology, and therapy with imatinib mesylate
    Koh, JS
    Trent, J
    Chen, L
    El-Naggar, A
    Hunt, K
    Pollock, R
    Zhang, W
    HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (02) : 565 - 574
  • [10] Imaging of Gastrointestinal Stromal Tumors before and after Imatinib Mesylate Therapy
    Shankar, S.
    Dundamadappa, S. K.
    Karam, A. R.
    Stay, R. M.
    van Sonnenberg, E.
    ACTA RADIOLOGICA, 2009, 50 (08) : 837 - 844